Akeso Reports Record H1 2026 Sales Driven by Immuno-Oncology Portfolio

Key Facts

1Akeso achieved record drug sales revenue of approximately RMB 1,803.2 million in the first half of 2026.

2The company's commercial sales revenue increased by 28.7% year-over-year during the reporting period.

In a move reflecting the accelerating growth within the Chinese biotechnology sector, Akeso announced robust financial results for the first half of 2026. According to reports, the company achieved record drug sales revenue of approximately RMB 1,803.2 million during this period. This performance was driven by the advancement of its global immuno-oncology strategy and the development of chronic disease treatments.

The company's commercial sales revenue increased by 28.7% year-over-year, highlighting the success of its bispecific antibody portfolio. Per market data, the company's shares trade under the ticker 9926.HK on the Hong Kong Stock Exchange, where the results demonstrated significant progress in product commercialization and the expansion of global clinical trials.

At the close of August 27, 2026, the price of 9926.HK stood at 101.2 HKD, having reached a day high of 101.6 HKD. Investors are monitoring the continued sales momentum into the second half of the year, particularly as several new drug candidates enter advanced stages of clinical development.